View ValuationCaina Technology 향후 성장Future 기준 점검 5/6Caina Technology (는) 각각 연간 48.8% 및 24.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 48.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 5.8% 로 예상됩니다.핵심 정보48.8%이익 성장률48.11%EPS 성장률Medical Equipment 이익 성장21.5%매출 성장률24.6%향후 자기자본이익률5.81%애널리스트 커버리지Low마지막 업데이트28 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jun 30Caina Technology Co., Ltd. to Report First Half, 2026 Results on Aug 26, 2026Caina Technology Co., Ltd. announced that they will report first half, 2026 results on Aug 26, 2026Declared Dividend • Jun 05Dividend of CN¥0.04 announcedShareholders will receive a dividend of CN¥0.04. Ex-date: 9th June 2026 Payment date: 9th June 2026 Dividend yield will be 0.1%, which is lower than the industry average of 2.2%.Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 7 highly experienced directors. Independent Director Bin Liu was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공고 • Apr 29Caina Technology Co., Ltd., Annual General Meeting, May 22, 2026Caina Technology Co., Ltd., Annual General Meeting, May 22, 2026, at 15:00 China Standard Time. Location: 1F, No. 23, Huanxi Road, Zhutang Town, Jiangyin, Jiangsu China공고 • Mar 31Caina Technology Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026Caina Technology Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026공고 • Dec 31Caina Technology Co., Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026Caina Technology Co., Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026공고 • Sep 30Caina Technology Co., Ltd. to Report Q3, 2025 Results on Oct 25, 2025Caina Technology Co., Ltd. announced that they will report Q3, 2025 results on Oct 25, 2025공고 • Jul 02Caina Technology Co., Ltd. to Report First Half, 2025 Results on Aug 28, 2025Caina Technology Co., Ltd. announced that they will report first half, 2025 results on Aug 28, 2025공고 • Apr 25Caina Technology Co., Ltd., Annual General Meeting, May 16, 2025Caina Technology Co., Ltd., Annual General Meeting, May 16, 2025, at 14:30 China Standard Time. Location: 1F, No. 23, Huanxi Road, Zhutang Town, Jiangyin, Jiangsu China공고 • Mar 31Caina Technology Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025Caina Technology Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025공고 • Dec 31Caina Technology Co., Ltd. to Report Fiscal Year 2024 Results on Apr 25, 2025Caina Technology Co., Ltd. announced that they will report fiscal year 2024 results on Apr 25, 2025New Risk • Nov 10New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 26% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (26% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (19% net profit margin).New Risk • Oct 30New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 19% Last year net profit margin: 28% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (19% net profit margin).Valuation Update With 7 Day Price Move • Oct 02Investor sentiment improves as stock rises 24%After last week's 24% share price gain to CN¥19.98, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 21x in the Medical Equipment industry in China. Total loss to shareholders of 48% over the past year.공고 • Sep 30Caina Technology Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024Caina Technology Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024New Risk • Sep 19New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 9.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 9.4% per year for the foreseeable future. High level of non-cash earnings (44% accrual ratio). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: CN¥0.068 (vs CN¥0.29 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.068 (down from CN¥0.29 in 2Q 2023). Revenue: CN¥83.8m (down 24% from 2Q 2023). Net income: CN¥8.15m (down 77% from 2Q 2023). Profit margin: 9.7% (down from 32% in 2Q 2023). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Medical Equipment industry in China.공고 • Jun 29Caina Technology Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024Caina Technology Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024Declared Dividend • May 16Dividend of CN¥0.40 announcedShareholders will receive a dividend of CN¥0.40. Ex-date: 21st May 2024 Payment date: 21st May 2024 Dividend yield will be 1.8%, which is lower than the industry average of 2.2%. Sustainability & Growth Dividend is covered by earnings (37% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 13% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 92% over the next 2 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Apr 20Full year 2023 earnings released: EPS: CN¥0.92 (vs CN¥1.35 in FY 2022)Full year 2023 results: EPS: CN¥0.92 (down from CN¥1.35 in FY 2022). Revenue: CN¥410.5m (down 12% from FY 2022). Net income: CN¥112.6m (down 31% from FY 2022). Profit margin: 27% (down from 35% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 29% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Medical Equipment industry in China.공고 • Apr 20Caina Technology Co., Ltd., Annual General Meeting, May 10, 2024Caina Technology Co., Ltd., Annual General Meeting, May 10, 2024, at 14:30 China Standard Time. Location: 1F, No. 23, Huanxi Road, Zhutang Town, Jiangyin, Jiangsu ChinaValuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥22.48, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 21x in the Medical Equipment industry in China. Total loss to shareholders of 39% over the past year.공고 • Mar 30Caina Technology Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024Caina Technology Co., Ltd. announced that they will report Q1, 2024 results on Apr 25, 2024Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥30.58, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 21x in the Medical Equipment industry in China. Total loss to shareholders of 21% over the past year.Valuation Update With 7 Day Price Move • Feb 02Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to CN¥23.40, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 19x in the Medical Equipment industry in China.공고 • Dec 29Caina Technology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024Caina Technology Co., Ltd. announced that they will report fiscal year 2023 results on Apr 19, 2024Valuation Update With 7 Day Price Move • Dec 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥36.17, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 25x in the Medical Equipment industry in China.Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: CN¥0.34 (vs CN¥0.28 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.34 (up from CN¥0.28 in 3Q 2022). Revenue: CN¥116.5m (up 13% from 3Q 2022). Net income: CN¥41.4m (up 20% from 3Q 2022). Profit margin: 36% (up from 33% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China.New Risk • Oct 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (44% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (6.4% average weekly change).Valuation Update With 7 Day Price Move • Oct 30Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥42.40, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 22x in the Medical Equipment industry in China.Reported Earnings • Aug 25Second quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.49 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.29 (down from CN¥0.49 in 2Q 2022). Revenue: CN¥110.3m (down 17% from 2Q 2022). Net income: CN¥35.4m (down 41% from 2Q 2022). Profit margin: 32% (down from 46% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China.공고 • Jul 18Caina Technology Co., Ltd. Announces Board AppointmentsCaina Technology Co., Ltd. held its 2nd Extraordinary General Meeting of 2023 on 14 July 2023, approved the appointment of Zha Lingyun, Cheng Rufa, Hou Peng as non-independent directors. Liu Bin, Wang Shanghu and Xia Liyang as independent directors. Ji Chunxia and Wu Yaqing as non-employee supervisors.Buying Opportunity • Jul 12Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 4.5%. The fair value is estimated to be CN¥47.49, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 19% over the last year. Earnings per share has declined by 18%. Revenue is forecast to grow by 144% in 2 years. Earnings is forecast to grow by 113% in the next 2 years.공고 • Jul 01Caina Technology Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023Caina Technology Co., Ltd. announced that they will report first half, 2023 results on Aug 25, 2023Buying Opportunity • May 16Now 32% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be CN¥48.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 19% over the last year. Earnings per share has declined by 18%. Revenue is forecast to grow by 144% in 2 years. Earnings is forecast to grow by 114% in the next 2 years.공고 • May 11Caina Technology Co., Ltd. Announces Cash Dividend for 2022, Payable on 16 May 2023Caina Technology Co., Ltd. announced 2022 final profit distribution plan to be implemented (A shares) as cash dividend/10 shares (tax included): CNY 4.50000000. Record date is 15 May 2023. Ex-date is 16 May 2023. Payment date is 16 May 2023.Reported Earnings • Apr 12Full year 2022 earnings released: EPS: CN¥1.76 (vs CN¥1.85 in FY 2021)Full year 2022 results: EPS: CN¥1.76. Revenue: CN¥465.5m (up 5.3% from FY 2021). Net income: CN¥161.9m (up 24% from FY 2021). Profit margin: 35% (up from 30% in FY 2021). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 40% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Medical Equipment industry in China.Board Change • Mar 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman & GM Jun Lu was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.이익 및 매출 성장 예측XSEC:301122 - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028907136N/A149112/31/2027762109N/A111112/31/202663487N/A4113/31/202642511-6614N/A12/31/20253576-7419N/A9/30/20253424-6354N/A6/30/202535229-4076N/A3/31/202535036-4289N/A12/31/2024388534105N/A9/30/202440977-4879N/A6/30/202442894-7591N/A3/31/2024454122-8191N/A12/31/2023410113-11187N/A9/30/2023382120-86130N/A6/30/2023368114-9887N/A3/31/2023391138-5178N/A1/1/2023465162-26139N/A9/30/202251117442170N/A6/30/202251616970186N/A3/31/202248213320130N/A1/1/202244213163160N/A9/30/202140910727117N/A6/30/20214019433125N/A3/31/202145512254139N/A12/31/202050513798170N/A12/31/201918132N/A58N/A12/31/201814320N/A21N/A12/31/20179313N/A0N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 301122 의 연간 예상 수익 증가율(48.8%)이 saving rate(2.4%)보다 높습니다.수익 vs 시장: 301122 의 연간 수익(48.8%)이 CN 시장(26%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: 301122 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: 301122 의 수익(연간 24.6%)이 CN 시장(연간 16%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 301122 의 수익(연간 24.6%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 301122의 자본 수익률은 3년 후 5.8%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/23 23:44종가2026/07/23 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Caina Technology Co., Ltd.는 2명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Feifei XuChina Merchants Securities (HK) Co., LtdWen DaiHuatai Research
공고 • Jun 30Caina Technology Co., Ltd. to Report First Half, 2026 Results on Aug 26, 2026Caina Technology Co., Ltd. announced that they will report first half, 2026 results on Aug 26, 2026
Declared Dividend • Jun 05Dividend of CN¥0.04 announcedShareholders will receive a dividend of CN¥0.04. Ex-date: 9th June 2026 Payment date: 9th June 2026 Dividend yield will be 0.1%, which is lower than the industry average of 2.2%.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 7 highly experienced directors. Independent Director Bin Liu was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공고 • Apr 29Caina Technology Co., Ltd., Annual General Meeting, May 22, 2026Caina Technology Co., Ltd., Annual General Meeting, May 22, 2026, at 15:00 China Standard Time. Location: 1F, No. 23, Huanxi Road, Zhutang Town, Jiangyin, Jiangsu China
공고 • Mar 31Caina Technology Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026Caina Technology Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026
공고 • Dec 31Caina Technology Co., Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026Caina Technology Co., Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026
공고 • Sep 30Caina Technology Co., Ltd. to Report Q3, 2025 Results on Oct 25, 2025Caina Technology Co., Ltd. announced that they will report Q3, 2025 results on Oct 25, 2025
공고 • Jul 02Caina Technology Co., Ltd. to Report First Half, 2025 Results on Aug 28, 2025Caina Technology Co., Ltd. announced that they will report first half, 2025 results on Aug 28, 2025
공고 • Apr 25Caina Technology Co., Ltd., Annual General Meeting, May 16, 2025Caina Technology Co., Ltd., Annual General Meeting, May 16, 2025, at 14:30 China Standard Time. Location: 1F, No. 23, Huanxi Road, Zhutang Town, Jiangyin, Jiangsu China
공고 • Mar 31Caina Technology Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025Caina Technology Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025
공고 • Dec 31Caina Technology Co., Ltd. to Report Fiscal Year 2024 Results on Apr 25, 2025Caina Technology Co., Ltd. announced that they will report fiscal year 2024 results on Apr 25, 2025
New Risk • Nov 10New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 26% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (26% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (19% net profit margin).
New Risk • Oct 30New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 19% Last year net profit margin: 28% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (19% net profit margin).
Valuation Update With 7 Day Price Move • Oct 02Investor sentiment improves as stock rises 24%After last week's 24% share price gain to CN¥19.98, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 21x in the Medical Equipment industry in China. Total loss to shareholders of 48% over the past year.
공고 • Sep 30Caina Technology Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024Caina Technology Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024
New Risk • Sep 19New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 9.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 9.4% per year for the foreseeable future. High level of non-cash earnings (44% accrual ratio). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: CN¥0.068 (vs CN¥0.29 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.068 (down from CN¥0.29 in 2Q 2023). Revenue: CN¥83.8m (down 24% from 2Q 2023). Net income: CN¥8.15m (down 77% from 2Q 2023). Profit margin: 9.7% (down from 32% in 2Q 2023). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Medical Equipment industry in China.
공고 • Jun 29Caina Technology Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024Caina Technology Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024
Declared Dividend • May 16Dividend of CN¥0.40 announcedShareholders will receive a dividend of CN¥0.40. Ex-date: 21st May 2024 Payment date: 21st May 2024 Dividend yield will be 1.8%, which is lower than the industry average of 2.2%. Sustainability & Growth Dividend is covered by earnings (37% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 13% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 92% over the next 2 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Apr 20Full year 2023 earnings released: EPS: CN¥0.92 (vs CN¥1.35 in FY 2022)Full year 2023 results: EPS: CN¥0.92 (down from CN¥1.35 in FY 2022). Revenue: CN¥410.5m (down 12% from FY 2022). Net income: CN¥112.6m (down 31% from FY 2022). Profit margin: 27% (down from 35% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 29% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Medical Equipment industry in China.
공고 • Apr 20Caina Technology Co., Ltd., Annual General Meeting, May 10, 2024Caina Technology Co., Ltd., Annual General Meeting, May 10, 2024, at 14:30 China Standard Time. Location: 1F, No. 23, Huanxi Road, Zhutang Town, Jiangyin, Jiangsu China
Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥22.48, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 21x in the Medical Equipment industry in China. Total loss to shareholders of 39% over the past year.
공고 • Mar 30Caina Technology Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024Caina Technology Co., Ltd. announced that they will report Q1, 2024 results on Apr 25, 2024
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥30.58, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 21x in the Medical Equipment industry in China. Total loss to shareholders of 21% over the past year.
Valuation Update With 7 Day Price Move • Feb 02Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to CN¥23.40, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 19x in the Medical Equipment industry in China.
공고 • Dec 29Caina Technology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024Caina Technology Co., Ltd. announced that they will report fiscal year 2023 results on Apr 19, 2024
Valuation Update With 7 Day Price Move • Dec 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥36.17, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 25x in the Medical Equipment industry in China.
Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: CN¥0.34 (vs CN¥0.28 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.34 (up from CN¥0.28 in 3Q 2022). Revenue: CN¥116.5m (up 13% from 3Q 2022). Net income: CN¥41.4m (up 20% from 3Q 2022). Profit margin: 36% (up from 33% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China.
New Risk • Oct 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (44% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (6.4% average weekly change).
Valuation Update With 7 Day Price Move • Oct 30Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥42.40, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 22x in the Medical Equipment industry in China.
Reported Earnings • Aug 25Second quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.49 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.29 (down from CN¥0.49 in 2Q 2022). Revenue: CN¥110.3m (down 17% from 2Q 2022). Net income: CN¥35.4m (down 41% from 2Q 2022). Profit margin: 32% (down from 46% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China.
공고 • Jul 18Caina Technology Co., Ltd. Announces Board AppointmentsCaina Technology Co., Ltd. held its 2nd Extraordinary General Meeting of 2023 on 14 July 2023, approved the appointment of Zha Lingyun, Cheng Rufa, Hou Peng as non-independent directors. Liu Bin, Wang Shanghu and Xia Liyang as independent directors. Ji Chunxia and Wu Yaqing as non-employee supervisors.
Buying Opportunity • Jul 12Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 4.5%. The fair value is estimated to be CN¥47.49, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 19% over the last year. Earnings per share has declined by 18%. Revenue is forecast to grow by 144% in 2 years. Earnings is forecast to grow by 113% in the next 2 years.
공고 • Jul 01Caina Technology Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023Caina Technology Co., Ltd. announced that they will report first half, 2023 results on Aug 25, 2023
Buying Opportunity • May 16Now 32% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be CN¥48.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 19% over the last year. Earnings per share has declined by 18%. Revenue is forecast to grow by 144% in 2 years. Earnings is forecast to grow by 114% in the next 2 years.
공고 • May 11Caina Technology Co., Ltd. Announces Cash Dividend for 2022, Payable on 16 May 2023Caina Technology Co., Ltd. announced 2022 final profit distribution plan to be implemented (A shares) as cash dividend/10 shares (tax included): CNY 4.50000000. Record date is 15 May 2023. Ex-date is 16 May 2023. Payment date is 16 May 2023.
Reported Earnings • Apr 12Full year 2022 earnings released: EPS: CN¥1.76 (vs CN¥1.85 in FY 2021)Full year 2022 results: EPS: CN¥1.76. Revenue: CN¥465.5m (up 5.3% from FY 2021). Net income: CN¥161.9m (up 24% from FY 2021). Profit margin: 35% (up from 30% in FY 2021). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 40% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Medical Equipment industry in China.
Board Change • Mar 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman & GM Jun Lu was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.